Drugs / TDF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07852091 Background | Oct 2023 → Dec 2026 expected | chronic hepatitis B virus infection | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07852091 ↗ |
| Route | Oral | “NAs(ETV/TDF/TAF), Once/day, 1 capsule/time, oral” NCT07852091 ↗ |